Ascites Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Ascites Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Ascites Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Ascites Market by downloading the comprehensive report from DelveInsight @ Ascites Treatment Market Size

 

Key Takeaways from the Ascites Market Report

• In September 2024:- Versantis AG- A Phase 2a, Open-label, Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of VS-01 on Top of Standard of Care (SOC), Compared to SOC Alone, in Adult Patients With Acute-on-Chronic Liver Failure (ACLF) Grades 1 and 2 and Ascites.
• It is estimated that the Ascites treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development.
• DelveInsight analysis indicates that in 2023, the US had approximately 153 thousand cases of Ascites due to Cirrhosis, accounting for the largest share in the 7MM.
• DelveInsight’s analysis revealed that in Japan during 2023, there were 5,355 instances of Grade I ascites attributed to cirrhosis. Additionally, more severe cases of Grade II and III ascites were recorded at 24,394 cases each in the same year.
• The leading Ascites Companies such as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
• Promising Ascites Therapies such as Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.

 

Gain a competitive edge in the Ascites Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Ascites Treatment Drugs

 

Ascites Epidemiology Segmentation in the 7MM

• Number of Ascites Cases by Malignancies
• Number of Ascites Cases due to Cirrhosis
• Severity-specific Cases of Ascites due to Cirrhosis
• Refractory Ascites Patients with Cirrhosis

 

Ascites Treatment Market Landscape

The treatment landscape of ascites due to cirrhosis include diuretics, paracentesis, insertion of a transjugular intrahepatic portosystemic shunt (TIPS), as well as managing complications to ascites such as spontaneous bacterial peritonitis (SBP). Mild and moderate ascites due to liver cirrhosis can be treated with dietary sodium restriction, treatment of the underlying disorder, fluid restriction, use of diuretics, and use of therapeutic paracentesis.

 

Discover key developments and opportunities in the Ascites Market. Click here to learn more from DelveInsight’s latest report @ Ascites Market Size

 

Ascites Drugs Market

The Ascites market for drugs targeting ascites is notably constrained. While certain treatments provide symptomatic relief, there is a significant lack of approved drugs addressing the condition’s underlying causes. This scarcity of targeted treatments reflects a major challenge in effectively managing the diverse manifestations of ascites, indicating a substantial need for innovative solutions and advancements in drug development for more comprehensive care.

 

Ascites Emerging Drugs Profile

• OCE-205: Ocelot Bio
• BIV201 (terlipressin): Biovie

 

Download DelveInsight’s Ascites Market report today and stay ahead in this rapidly evolving field. @ Ascites Clinical Trials

 

Scope of the Ascites Market Report

• Coverage- 7MM
• Ascites Companies- as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
• Ascites Therapies- Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.
• Ascites Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement

 

Download the report to understand which factors are driving Ascites Market Trends @ Ascites Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Ascites Market Overview at a Glance

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Emerging Therapies

11 Ascites: Seven Major Market Analysis

12 Unmet Needs

13 SWOT Analysis

14 KOL Views

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/